The importance of developing personalized risk prediction estimates has become increasingly evident in recent years.
Policies to increase preventive testing in developing countries should include subsidies towards treatment costs.
Few patients 75 years of age and older participate in clinical trials, thus whether adjuvant chemotherapy for stage III colon cancer (CC) benefits this group is unknown.
Health care in the United States is notoriously expensive while often failing to deliver the care recommended in published guidelines.
This chapter presents an overview of computational modeling as a tool for multilevel cancer care and intervention research.
This Statistical Brief presents data from the Healthcare Cost and Utilization Project (HCUP) on hospital stays for cancer care in individuals under 18 years of age in 2009.
There is a growing emphasis on promoting medical treatments that provide the most benefits relative to their costs.
Assessments of the medical and economic value of therapies in diseases such as cancer traditionally focus on average or median gains in patients' survival.
The higher-cost US system of cancer care delivery may be worth it, although further research is required to determine what specific tools or treatments are driving improved cancer survival in the United States.
The addition of oxaliplatin to 5-FU appears to be associated with better survival among patients receiving adjuvant colon cancer treatment in the community.
Cancer is the leading cause of death among men and women under age 85.
This study demonstrates that the CanCORS Consortium was successful in enrolling a demographically representative sample within the CanCORS regions.
Physician co-management, representing joint participation in the planning, decision-making, and delivery of care, is often cited in association with coordination of care. Yet little is known about how physicians manage tasks and how their management style impacts patient outcomes.
Experts agree on many key issues regarding anaplastic large cell lymphoma in women with breast implants, but substantial research is needed to improve our understanding of the epidemiology, clinical aspects, and biology of this disease.
US and Canadian differences in cancer screening due to each country's guidelines can potentially explain cross-country differences in breast cancer mortality and affect interpretation of international comparisons of cancer statistics.
Decreased use of myeloid colony-stimulating factors in patients at lower or intermediate risk of febrile neutropenia from high-risk chemotherapy regimens could yield substantial cost savings without compromising patient outcomes.
Breast implants appear to be associated with a rare form of lymphoma, but there is not yet evidence to show that the cancer is caused by implants or to suggest an underlying mechanism for how the disease might develop.
Cancer Quality-ASSIST indicators are useful for practical quality assessment of cancer end-of-life care in an academic medical center.
The largest-ever assessment of high-deductible health plans find that such plans significantly cut health spending but families with such plans also cut preventive care such as cancer screening, childhood immunizations, and routine diabetes testing.
The use of patient navigators-individuals who perform outreach, coordination, and education across language and cultural barriers-improved breast cancer quality of care in a public hospital and may help reduce disparities in quality of cancer care.
RAND® is a registered trademark. Copyright © 1994-2013 RAND Corporation. Last Modified: September 15, 2010 Site Feedback »